RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.
KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.
Aminexil is used to strengthen hair roots but stopping it may lead to hair thinning, unlike minoxidil which has more complex effects. The user did not use finasteride or minoxidil due to concerns about side effects.
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.
The conversation discusses Dr. Blake Bloxham's experiment with Verteporfin for hair loss, with one person suggesting more doctors should try it as it seems beneficial. Another comment notes that results at 4-5 months were not very impressive.
A new company is introducing a topical treatment combining Minoxidil, Finasteride, and Bimatoprost for hair loss. Users are also inquiring about updates on a minoxidil-enhancing shampoo from Applied Biology.
The conversation warns against buying RU58841 from Amazon due to concerns about product authenticity and recommends purchasing from trusted sources like Minoxidilmax and Anageninc.
The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.
The conversation is about hair loss treatments, specifically Minoxidil (Min) and Finasteride (Fin). The original poster is considering using Min and other treatments but is hesitant about Fin, while the responses vary, with some advocating for early use of Fin and others warning about potential side effects.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
User shared 8-month hair loss treatment progress using topical fin/min, topical dut, mk677, RU, and microneedling. They experienced watery semen as a side effect but saw significant improvement in hair growth.
The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.
The user is disappointed with their hair loss progress after six months of using oral medications, laser therapy, microneedling, and vitamin D supplements. They are considering exosome therapy but are unsure of its effectiveness and are seeking advice on whether to continue or try other treatments.
Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.
RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.
Minoxidil's effectiveness varies due to genetic differences in the SULT1A1 enzyme, affecting how well it converts to its active form, minoxidil sulfate. Hyper-responders may experience rapid hair growth and increased side effects, such as pericardial effusion, even at low doses.
The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.